Mubucho (Dasatinib)

Dasatinib, the active ingredient in Mubucho, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Mubucho as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres and pharmacies worldwide, with distribution aligned to EU regulatory standards and quality assurance protocols. The company ensures batch traceability, temperature‑controlled logistics where required, and compliance with import‑export documentation for global markets.

Dasatinib targets BCR‑ABL and Src family kinases, addressing malignancies within the myeloproliferative and lymphoid disease spectrum.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation, improves hematologic and cytogenetic response, and extends overall survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission and prolongs disease‑free survival in adult patients. - Advanced or blast phase CML: provides disease control when other tyrosine kinase inhibitors are ineffective or not tolerated.

Dasatinib may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, often transient. - Fatigue: persistent tiredness affecting daily activities. - Rash: skin erythema or pruritus.

Serious or Rare Side Effects: - Pleural effusion: accumulation of fluid around the lungs, may require drainage. - Pulmonary hypertension: elevated pressure in pulmonary arteries, potentially life‑threatening. - Severe hemorrhage: bleeding events including gastrointestinal or intracranial. - Cardiac dysfunction: reduced left ventricular ejection fraction or heart failure.

Before initiating Dasatinib therapy, clinicians should consider several precautionary measures to ensure patient safety. - Monitor blood counts: perform baseline and regular CBC to detect myelosuppression. - Assess cardiac function: evaluate for pre‑existing pulmonary hypertension or heart failure. - Evaluate infection risk: screen for active infections and vaccinate appropriately. - Avoid strong CYP3A4 inhibitors: concomitant use may increase dasatinib exposure and toxicity. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Dasatinib interacts with several medicines; awareness of these interactions helps to minimize adverse effects and maintain efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase dasatinib plasma levels. - Antacids containing aluminum or magnesium: reduce dasatinib absorption if taken simultaneously. - QT‑prolonging agents (e.g., sotalol, quinidine): may exacerbate cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may lower dasatinib concentrations, reducing effectiveness. - Warfarin: dasatinib may enhance anticoagulant effect, requiring INR monitoring.